WATERTOWN, Mass – pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing sustained release, drug delivery products for treating eye diseases, today announced that it has signed two funded technology evaluation agreements with a leading global pharmaceutical company. The agreements will each evaluate the use of pSivida’s Durasert™ technology to deliver a specific compound to treat a significant ophthalmic disease.
“We are very pleased to be working with this leading global pharmaceutical company,” said Dr. Paul Ashton, president and CEO of pSivida. “Our strategy includes partnering product development with market leaders in appropriate circumstances, allowing us to expand our reach beyond our own product development. This opportunity fits that criteria, and we are excited about the potential products.”
About pSivida Corp.
pSivida Corp. (www.psivida.com) headquartered in Watertown, MA, is a leader in the development of sustained release, drug delivery products for treating eye diseases. pSivida developed three of only four back of the eye implants approved by the FDA (Vitrasert® and Retisert®, licensed to Bausch & Lomb; and ILUVIEN®, licensed to Alimera Sciences). pSivida’s lead product candidate, Medidur™ for the treatment of posterior uveitis, is currently in pivotal phase III clinical trials. pSivida is also involved in the development of products focused on ocular and systemic delivery of biologics and drugs to treat wet and dry age-related macular degeneration (AMD), glaucoma, osteoarthritis and other diseases. These products are in preclinical development utilizing pSivida’s two core technology platforms: Durasert™ and/or Tethadur™.
Help employers find you! Check out all the jobs and post your resume.
“We are very pleased to be working with this leading global pharmaceutical company,” said Dr. Paul Ashton, president and CEO of pSivida. “Our strategy includes partnering product development with market leaders in appropriate circumstances, allowing us to expand our reach beyond our own product development. This opportunity fits that criteria, and we are excited about the potential products.”
About pSivida Corp.
pSivida Corp. (www.psivida.com) headquartered in Watertown, MA, is a leader in the development of sustained release, drug delivery products for treating eye diseases. pSivida developed three of only four back of the eye implants approved by the FDA (Vitrasert® and Retisert®, licensed to Bausch & Lomb; and ILUVIEN®, licensed to Alimera Sciences). pSivida’s lead product candidate, Medidur™ for the treatment of posterior uveitis, is currently in pivotal phase III clinical trials. pSivida is also involved in the development of products focused on ocular and systemic delivery of biologics and drugs to treat wet and dry age-related macular degeneration (AMD), glaucoma, osteoarthritis and other diseases. These products are in preclinical development utilizing pSivida’s two core technology platforms: Durasert™ and/or Tethadur™.
Help employers find you! Check out all the jobs and post your resume.
